US Equities Analysis

ALGN — Align Technology

ALGN Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 12.21B.

1.2 Competition

The industry is highly competitive with low barriers to entry and significant rivalry among existing players. Beta of 1.67 reflects elevated volatility from competitive dynamics. Companies compete on pricing, innovation, and scale.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 16.59%
Profit Margins 10.5%
Return on Equity 10.82%
Return on Assets 7.33%
Free Float 0.07B
Short Int % Utilisation 7.38%

2.2 Growth

Metric Value
Revenue Growth 6.2%
Free Cash Flow 0.54B
EBITDA 12.65 (Ratio)
Enterprise Value 11.27B
EV/Revenue 2.75
EV/EBITDA 12.65

Revenue growth of 6.2% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) -12.87%
Risk / Std Dev (Ann.) 49.60%
Sharpe Ratio (rf=4.5%) -0.35
Beta 1.67

2.5 Valuation

Metric Value
P/E (Forward) 13.78
Price/Book 2.91
EV/Revenue 2.75
EV/EBITDA 12.65
Enterprise Value / NOPAT 15.81
FCF Yield (%) 4.47%
Price / Earnings 28.32
Price / Book 2.91
Enterprise Value / EBITDA 12.49

Forward P/E of 14x is within a reasonable range for the company’s peer group.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of -12.9% with annualised volatility of 49.6%, yielding a Sharpe ratio of -0.35 (rf=4.5%). The risk-adjusted return is below the risk-free rate, suggesting compensation for risk may be inadequate. With a beta of 1.7, the stock is significantly more volatile than the market — it amplifies both upside and downside moves.


us-equitystockequityalgnhealth-carehealth-care-suppliesnasdaq